Figure 1
Figure 1. Clinical pictures and sVCAM-1 plasma levels in patients with edematous skin cGVHD. (A) Clinical pictures of 6 patients: (upper) inflammatory pitting edema and (lower) sclerodermatous evolution during follow-up. (B) Increased plasma sVCAM-1 levels in patients with edematous and lichenoid cGVHD. Scatter plots show plasma sVCAM-1 concentrations as measured by enzyme-linked immunosorbent assay in 9 patients with edematous skin cGVHD, 9 patients with lichenoid skin cGVHD, 9 patients with sclerodermatous skin cGVHD, 9 patients with hematopoietic stem cell transplantation but no cGVHD, and 9 healthy donors. Each dot represents an individual subject, and horizontal bars represent group means. Significant differences between group means are indicated: *P < .01 (Mann-Whitney nonparametric test).

Clinical pictures and sVCAM-1 plasma levels in patients with edematous skin cGVHD. (A) Clinical pictures of 6 patients: (upper) inflammatory pitting edema and (lower) sclerodermatous evolution during follow-up. (B) Increased plasma sVCAM-1 levels in patients with edematous and lichenoid cGVHD. Scatter plots show plasma sVCAM-1 concentrations as measured by enzyme-linked immunosorbent assay in 9 patients with edematous skin cGVHD, 9 patients with lichenoid skin cGVHD, 9 patients with sclerodermatous skin cGVHD, 9 patients with hematopoietic stem cell transplantation but no cGVHD, and 9 healthy donors. Each dot represents an individual subject, and horizontal bars represent group means. Significant differences between group means are indicated: *P < .01 (Mann-Whitney nonparametric test).

Close Modal

or Create an Account

Close Modal
Close Modal